International Myeloma Workshop 2015 Meeting Highlights

Please Log In or Register to continue.

Release Date: October 27, 2015
Expiration Date: October 27, 2016

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The International Myeloma Workshop (IMW) is an important biannual event held under the auspices of the International Myeloma Society where emerging advances in the biology and treatment of multiple myeloma (MM) are presented, along with debates centered on areas of controversy, as well as discussions that seek consensus among the world’s leading multiple myeloma experts regarding the most appropriate strategies to treat and manage this hematologic malignancy. The IMW 2015 meeting, held in Rome, Italy, in September 2015, was remarkable since it comes at a time of significant practice change regarding the diagnostic criteria for multiple myeloma, approaches to staging and risk-stratifying patients, adapting therapy for elderly and/or frail patients, and includes anticipated updates to recommendations for the monitoring of response to treatment. This has happened in an environment where treatment goals now reflect the ability of new regimens to provide unprecedented depth of response, making the evaluation of minimum residual disease (MRD) assessment an important and relevant prognostic consideration in practice. In addition, the outcomes of trials that seek to address some of the most outstanding questions in MM practice today are soon to be released, including upfront versus delayed transplant, and fixed duration versus continuous maintenance therapy in transplant-eligible patients. As a further consideration, new regimens and treatment strategies are emerging for multiple myeloma, including next-generation proteasome inhibitors, immunotherapies, and targeted therapies heralding an era of precision medicine that promises to further significantly improve the course of this disease for the vast majority of patients, perhaps even those who have been at greatest risk for progression and whose disease-related factors would historically indicate poor prognosis, while also providing better overall quality of life

Join our world-leading team Managing Myeloma expert faculty members, including Drs. Sergio Giralt, Sagar Lonial, Sundar Jagannath, Shaji Kumar, Noopur Raje, and our newest up and coming faculty contributor Dr. Joshua Richter, as they provide insight regarding the most important issues that impact multiple myeloma practice today, filmed live at the IMW 2015 meeting.

Target Audience

This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in multiple myeloma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Recognize IMWG updates to criteria for the diagnosis of multiple myeloma, as well as the new Revised International Staging System and the consequences of those updates to practice
  • Recall key controversies in multiple myeloma practice today, the evidence and rationale that supports various sides, and the trials whose outcomes may address these outstanding questions
  • Identify new regimens and agents that are merging for the treatment and management of multiple myeloma, and how they are anticipated to be used during the life cycle of the disease

Agenda

IMW 2015: The Important Questions in the United States and the Trials that Are Being Done to Answer Them – Sergio A. Giralt, MD, FACP

IMW 2015: A New Era of Immunotherapy for Multiple Myeloma – Sundar Jagannath, MD

IMW 2015: Expanding Options for Proteasome Inhibition and the Evaluation and Role of Minimum Residual Disease in Today’s Practice – Shaji K. Kumar, MD

IMW 2015: Recent Updates to Practice Recommendations from the International Myeloma Working Group – Sagar Lonial, MD

IMW 2015: Updates on Proteasome Inhibitors and New Classes of Agents for Multiple Myeloma – Noopur Raje, MD

IMW 2015: Combination versus Sequential Therapy for Multiple Myeloma – Joshua Richter, MD

Instructions for Participation and Credit

This activity is eligible for credit through October 27, 2016. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biographies

Sergio A. Giralt, MD, FACP
Chief, Attending Physician
Adult Bone Marrow Transplant Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Dr. Sergio Giralt received his medical degree from Universidad Central de Venezuela and completed his postgraduate internship at the University Hospital of Caracas. He also completed an internal medicine residency at Good Samaritan Hospital in Cincinnati, Ohio, and a postdoctoral fellowship in hematology and oncology at The University of Texas MD Anderson Cancer Center. Dr. Giralt is currently professor of medicine at Weill Cornell College of Medicine and the chief of the Adult Bone Marrow Transplant Service in the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City.

Board certified in internal medicine, hematology, and medical oncology, Dr. Giralt holds memberships in several professional societies, including the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the North American Society of Blood and Bone Marrow Transplantation, among others. He is a highly sought speaker, lecturer, and presenter who has published hundreds of research articles and abstracts in peer-reviewed literature. Additionally, he is an editorial reviewer for several journals including Blood, Bone Marrow Transplantation, Clinical Cancer Research, Journal of Clinical Oncology, and The Oncologist.

Dr. Giralt’s research focus has been on improving treatments for older patients who have acute and chronic leukemia.

Sundar Jagannath, MD
Professor of Medicine
Mount Sinai School of Medicine
Director, Multiple Myeloma Program
Tisch Cancer Institute
Mount Sinai Hospital
New York, New York

Dr. Sundar Jagannath received his medical degree at Maharaja Sayajirao University in Baroda, India, and continued his medical training with a fellowship in immunovirology at McMaster University Medical Center in Hamilton, Ontario, Canada. His residency was completed at the Bronx-Lebanon Hospital in New York City, and at Harper-Grace Hospital, Wayne State University in Detroit, Michigan. Dr. Jagannath also completed a medical oncology fellowship at University of Texas System Cancer Center–MD Anderson Hospital and Tumor Institute in Houston, Texas. Dr. Jagannath is currently director of the Multiple Myeloma Program at Tisch Cancer Institute, Mount Sinai Hospital, and professor of medicine at Mount Sinai School of Medicine, New York, New York.

Dr. Jagannath is a board-certified specialist in internal medicine and medical oncology and is a board member of the Society of Hematologic Oncology. In addition, he is an active member of the American College of Physicians, American Society of Clinical Oncology, American Society of Hematology, and the American Society for Bone and Marrow Transplantation. A renowned expert in multiple myeloma and bone marrow transplantation, Dr. Jagannath has published extensively on these topics and is often an invited presenter at professional organizations’ annual meetings. He is a reviewer for several journals including American Journal of Hematology, Blood, Bone Marrow Transplantation, and Journal of Clinical Oncology, and is editor-in-chief of Clinical Lymphoma, Myeloma & Leukemia.

Shaji K. Kumar, MD
Professor of Medicine
Mayo Clinic College of Medicine
Consultant, Division of Hematology
Medical Director, Cancer Clinical Research Office
Mayo Clinic
Rochester, Minnesota

Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. He is currently the medical director for the Cancer Center Clinical Research Office which oversees the development, activation, conduct, and monitoring of interventional trials across the three site Mayo Clinic Cancer Center.

Certified by the American Board of Internal Medicine (ABIM) in internal medicine, medical oncology, and an ABIM diplomate in hematology, Dr. Kumar holds membership in several professional organizations including the American Society of Hematology, American Society of Clinical Oncology, American Association for Cancer Research, American Society of Blood and Marrow Transplantation, the Association of Physicians of India, and the European Hematology Association. He has published numerous articles, abstracts, editorials, and letters in the peer-reviewed literature, including Blood, Journal of Clinical Oncology, Leukemia, American Journal of Hematology, British Journal of Haematology, and Bone Marrow Transplantation. He is also a member of the editorial board for several journals including American Journal of Hematology, European Journal of Clinical and Medical Oncology, and Leukemia.

Dr. Kumar’s research focuses on the development of novel drugs for the treatment of myeloma, and he has presented nationally and internationally. He is the principal investigator of several phase 1 and phase 2 clinical trials exploring new drugs and combinations for newly diagnosed and relapsed myeloma. His laboratory is focused on understanding the role of bone marrow microenvironment in the development and progression of myeloma.

Sagar Lonial, MD
Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is a professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University where he is also the vice chair of clinical affairs, as well as director of the Translational Research for the B-Cell Malignancy Program.

He is involved in numerous professional organizations including the American Society of Clinical Oncology, American Society of Hematology, and the American Society for Blood and Marrow Transplantation. In addition, Dr. Lonial serves on the editorial board of the Journal of Clinical Oncology, and Leukemia, and is the myeloma editor for Clinical Lymphoma, Myeloma & Leukemia, and also serves as an invited and ad hoc reviewer for several publications including Blood, Haematologica, Clinical Cancer Research, The New England Journal of Medicine, and others. Dr. Lonial has authored/coauthored over 200 publications and recently was awarded the Celgene ‘Young Investigator’ Award, the MMRF ‘Top 15 Innovator’ Award, and the MMRC ‘Center of the Year’ award.

Dr. Lonial’s research interest is on combination therapy in B-cell malignancies focusing on myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular targeted agents for B-cell tumors as well as target discovery and validation.

Noopur Raje, MD
Director, Multiple Myeloma Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University, India. She has trained in internal medicine at Massachusetts General Hospital (MGH) and has completed a fellowship in hematology and medical oncology at the Dana-Farber Cancer Institute, Boston. Dr. Raje has a joint faculty appointment at MGH and Dana-Farber Cancer Institute. She is an associate professor of medicine at Harvard Medical School and is the director of the Multiple Myeloma Program, Medical Oncology, at MGH. As a hematologist/oncologist at MGH, Dr. Raje’s primary focus is in multiple myeloma and related research. Her laboratory focuses on bone biology and the development of novel therapeutics for multiple myeloma, as well as identifying and validating novel targets and translating them into clinical trials.

Dr. Raje is a member of the American Medical Association, America Society of Hematology, American Society of Clinical Oncology, and American Association of Cancer Research, she is also an ad hoc reviewer for several journals including Blood, Clinical Cancer Research, Leukemia, and the American Journal of Hematology. Dr. Raje is the recipient of several awards and has published extensively in the field of multiple myeloma research. Her hope is to continue pursuing laboratory and clinical research in the area of multiple myeloma with the goal of translating her efforts to the improvement of patients’ lives.

Joshua Richter, MD
Clinical Assistant Professor
Department of Medicine
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, New Jersey

Dr. Joshua Richter received his medical degree from New York Medical College. He completed a multiple myeloma residency at St. Vincent’s Hospital – New York Medical College, and a hematology/oncology fellowship at Yale Cancer Center, Yale University. Dr. Richter is a clinical assistant professor in the Department of Medicine at Hackensack University Medical Center in Hackensack, New Jersey.

Dr. Richter is board certified in internal medicine, hematology, and medical oncology. He has been published in numerous oncology journals, including Blood, Clinical Immunology and Leukemia & Lymphoma. Dr. Richter has worked at some of the world’s most prestigious cancer centers and specializes in multiple myeloma at John Theurer Cancer Center which allows the division to further expand its internationally-recognized myeloma clinical and research practice.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-15-054-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.
MediCom NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 15-054-020

Disclosure

As an organization accredited by theAccreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures

Dr. Sergio Giralt has received honoraria related to formal advisory activities and as a consultant from Amgen Inc., Celgene Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson Services, Inc., Novartis AG, Sanofi, and Takeda Oncology. He has received grant support related to research activities from Celgene, Johnson & Johnson, Sanofi, and Takeda Oncology.

Dr. Sundar Jagannath has received honoraria related to formal advisory activities from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., and Novartis AG.

Dr. Shaji Kumar has received honoraria as a consultant and grant support related to research activities from Celgene Corporation, Janssen Pharmaceuticals, Inc., Onyx, Sanofi, and Takeda Oncology, in addition to honoraria as a consultant from NOXXON Pharma AG and Skyline Diagnostics B.V.

Dr. Sagar Lonial has received honoraria as a consultant from Bristol-Myers Squibb, Celgene Corporation, Janssen Pharmaceuticals, Inc., Novartis AG, Onyx, and Takeda Oncology.

Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Celgene Corporation, Onyx, and Takeda Oncology. She has received grant support related to research activities from Acetylon Pharmaceuticals, Inc. and Eli Lilly and Company.

Dr. Joshua Richter has received honoraria related to speakers’ bureau activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Inc., and Takeda Oncology, as well as formal advisory activities from Celgene and Takeda Oncology.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, and Eugene R. Tombler, PhD, FACME, medical director, oncology, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Drs. Giralt, Kumar, Lonial, and Richter have indicated that they do intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Jagannath and Raje have indicated that they do not intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Drs. Giralt, Kumar, and Richter have indicated that they do intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Drs. Jagannath, Lonial, and Raje have indicated that they do not intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at info@managingmyeloma.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Amgen Inc., Celgene Corporation and Takeda Oncology

©2015 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

Please Log In or Register to continue.